Company History Timeline — 2010s

2010

  • Agilent purchases Varian, Inc., the largest acquisition to date in the company's history. The majority of Varian's product lines join Agilent's Chemical Analysis Group (CAG), while the Life Sciences Group (LSG) gains key businesses, including nuclear magnetic resonance (NMR).

  • Agilent and the National Center for Food Safety and Technology (NCFST) enter into a collaboration to develop new scientific methods for analyzing food borne illnesses and food quality. As a part of this effort, Agilent provides NCFST with an extensive assortment of the latest analytical chemistry and life science instrumentation, along with training and applications support.

2011

  • Agilent joins in a collaborative effort with the newly formed Synthetic Biology Institute at UC Berkeley as its first Industry Member.

  • China becomes the first country outside the United States to achieve over $1 billion in orders with Agilent during a single year.

2012

  • Agilent's board of directors declares the first quarterly cash dividend in the company's history—10 cents per share.

  • Agilent joins forces with the University of California at Davis and the U.S. Food and Drug Administration to initiate the 100,000 Genome Project, a massive five-year effort to improve food safety. The project will harness cutting-edge technology to enable faster responses to foodborne outbreaks.

  • Dako, a cancer diagnostics company headquartered in Denmark, becomes the largest acquisition in Agilent's history. The acquisition enables Agilent to grow its diagnostics business and expand its role in life sciences. About 1,000 Dako employees join Agilent. Agilent's milestones for the Dako brand provides a view of historical information about it's Dako brand.

2013

  • Agilent opens two offices in Hanoi and Ho Chi Minh City to provide customers in Vietnam with sales, applications and support services. As one of the fastest-developing business areas in the world, Vietnam is a critical part of Agilent's emerging markets strategy.

  • On Sept. 19, Agilent announces "the most profound change in its history," according to Chief Executive Officer Bill Sullivan. The company will separate into two industry-leading public companies, one comprising the life sciences, diagnostics and applied markets (LDA) businesses, which will retain the Agilent name, and the second consisting of the electronic measurement (EM) business. Sullivan will continue to head Agilent; Agilent President and Chief Operating Officer Ron Nersesian will become president and CEO of the new company, to be named.

2014

  • Agilent announces its CEO transition plan in September 2014 with William P. (Bill) Sullivan's retirement next year, naming Mike McMullen as CEO-elect for March 2015. As a first step in the transition, Mike is appointed president and chief operating officer, effective immediately. Bill will become an advisor in March until his retirement at the end of fiscal 2015.

  • Agilent completes the spinoff of its former electronic measurement business—Keysight Technologies—on Nov. 1. Keysight begins trading on the New York Stock Exchange on Nov. 3 under the symbol KEYS.

2015

  • Agilent acquired Seahorse Bioscience, an industry leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.

  • Agilent Introduced the industry's most sensitive GC/MSD system – the Agilent 5977B High Efficiency Source (HES) GC/MSD system, a tandem gas chromatograph and mass spectrometer that delivers lower limits of detection than any other instrument in its class.

  • Agilent launched its most robust Triple Quadrupole Mass Spectrometer engineered to be Agilent's most robust triple quadrupole system ever, the 6470 delivers attogram-level sensitivity and accurate quantitation with up to six orders of linear dynamic range.

  • Agilent acquired Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data.

  • Agilent introduced the new 6545 Q-TOF Mass Spectrometry system. It includes advances in hardware and software that make it both more reliable and easier to use for trace-level analysis of small-molecule compounds in applications such as food safety, environmental testing, forensic toxicology and pharmaceuticals.

  • Mike McMullen is elected Agilent CEO by the board of directors, and on March 18, 2015, becomes the third president and CEO in the company's history, replacing Bill Sullivan.

2016

  • Agilent acquired Multiplicom N.V., a leading european diagnostics company with state-of-the-art genetic testing technology and products. This acquisition enhances Agilent's next-generation sequencing workflow capabilities.

  • Agilent unveiled transformational technology for Gas Chromatography with the Intuvo 9000 GC System. Click-and-run connections eliminate ferrules, guard-chip technology extends column life, and the trim-free column eliminates retention time shifts due to column trimming maintenance.

  • Agilent completed asset acquisition of iLab Solutions, a leader in cloud-based laboratory Management software.  Allowing our customers to easily and accurately book time, bill and invoice for projects, manage studies, generate reports and business intelligence, and to schedule instruments reservations across multiple projects.

  • Agilent introduced a new Atomic Spectroscopy Platform for multiple analytical applications delivering greater speed and precision than any other ICP-OES system. The 5110 ICP-OES will enable scientists to perform faster, more precise ICP-OES analysis in food, environmental and pharmaceutical testing as well as for mining and industrial applications.

  • Agilent made an $80 million investment in Lasergen, an emerging biotechnology company. Agilent acquired a 48-percent ownership stake and has join the board. Agilent's investment and collaboration are designed to accelerate Lasergen's work in commercializing their novel technology, focused on developing a sequencing workflow aimed at clinical applications.

  • Agilent introduced InfinityLab, a product family of liquid chromatography instruments, columns and supplies. A key element is the new Agilent 1260 Infinity II liquid chromatography system, which brings high-end technology from Agilent's flagship 1290 Infinity II LC into the company's core platform.

  • Agilent introduced first commercial software for Metabolic Flux Analysis to help researchers analyze qualitative metabolic flux-tracking the different pathways a metabolite participates in under different biological experiments.

2017

  • Agilent acquired Cobalt Light System, accelerating Agilent's entry into the high-growth Raman Spectroscopy Market and expanding its value proposition for pharmaceutical and biopharma customers.

  • Agilent introduced the GC/Q-TOF System – a third-generation instrument enabling greater exploration of unknown chemical samples - delivering high-resolution, accurate-mass system designed for laboratories doing food and environmental testing, life sciences research, forensics and chemical analysis.  

  • Agilent expanded its portfolio of scientific instruments with the new research-grade 6495B Triple Quadrupole LC/MS system that provides even greater sensitivity and accuracy for applications such as peptide quantitation, food safety, environmental testing, clinical research and forensic toxicology. The 6495B provides improved mass range, scan speed and polarity switching – all of which enable scientists to better analyze molecules from a wide array of sample matrices.

  • Agilent broadened its biopharma portfolio with the AdvanceBio LC/Q-TOF MS 6545XT system.  Agilent's solutions built around the 6545XT enable scientists to characterize biomolecule structure and function more efficiently than ever, resulting in reduced time to market and improved drug efficacy.

2018

  • Agilent signed an agreement to acquire the remaining shares of Lasergen, Inc., an emerging biotechnology company focused on research and development of innovative technologies for DNA sequencing, for $105 million.

  • Agilent acquired privately-held Advanced Analytical Technologies, Inc., a provider of capillary electrophoresis-based (CE) solutions for fully-automated analysis of a range of molecules for $250 million in cash. This acquisition enhances Agilent's existing expertise and technology, while giving customers a more comprehensive set of solutions.

  • Agilent and Imperial College London signed a strategic scientific collaboration agreement that combined  Agilent's leading analytical technologies with Imperial's outstanding researchers.   

  • Agilent formed a strategic scientific collaboration with the University of Southern California Michelson Center for Convergent Bioscience to create an Agilent Center of Excellence (COE) in Biomolecular Characterization.

  • Agilent named Company-of-the-Year by Instrument Business Outlook, citing impressive growth, the right solutions and strategy, and the right team.

  • Agilent acquired Ireland-based Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. This acquisition expands Agilent's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.

 

< Back